The authors found that the anti-LAT1 antibodies reduced proliferation of gastric and lung cancer cells in vitro and growth of colon cancer cells in vivo [81], suggesting that targeting LAT1 by monoclonal antibodies might be an alternative therapeutic option. The gene discussed is SLC7A5; the disease is lung carcinoma.